MDBriefCase will be unavailable due to maintenance from Sunday, January 14 11PM to Monday, January 15 1AM ET.

ICAN
Integrated Cancer Education for Oncology Pharmacists

The role of oncology pharmacists in the care of patients with cancer is critical given the complexities related to cost, tolerability, safety of oral oncology medications, issues of access, monitoring and follow-up of patients receiving this therapy. 

The Novartis Virtual Learning Series is designed to keep oncology pharmacists informed on the evolving body of knowledge in oncology and to help pharmacists implement new best processes at their clinical settings for better patient outcomes.

Learning Assets

Our virtual library of learning resources allows pharmacists to learn at their own pace and engage with the material in a variety of formats: accredited patient case modules and video-based presentations.

Learning Aims

Provide the latest clinical information and resources to help oncology pharmacists to enhance the care of patients with cancer who receive oncology treatments. 

Learning Objectives

  • Boost oncology pharmacists‚Äô leadership and knowledge in Oncology and help them implement highly specialised therapeutic area guidelines to secure best patient outcomes.
  • Provide world-class online education for oncology pharmacists
  • Drive awareness of the burden of disease, such as solid tumour cancers, haematology cancers, and showcase the value of innovative treatments in the Kingdom of Saudi Arabia.

On-Demand Webinar

Enhancing Oncology Care for Breast and Lung Cancer Patients in the Kingdom of Saudi Arabia

Understand the current landscape of approved therapies for breast cancer and lung cancer, with a focus on targeted therapy and immunotherapy.

Plus: learn how you, as a pharmacist, can collaborate within a multidisciplinary team to support patients throughout their oncology journey, from diagnosis through treatment and follow-up.

Faculty

Majed Alshamrani, PharmD, MBA, BCPS
Meteb Al-Foheidi, MD
Nora A. Alkhudair, Assistant Professor, PharmD
Hamed Alhussaini, MD

Continuing Medical Education Modules

Accredited continuing medical education modules, featuring real-world patient cases, will help pharmacists to enhance the care of patients with cancer who receive oncology treatments, as well as stay up to date on new practices and guidelines. These modules will review international approaches as well as therapeutic options for four of the most frequently diagnosed cancers in the Kingdom of Saudi Arabia.

Straight Talk on COVID-19 Series

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

 

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

MARCH
30

5:00 PM ‚Äď 8:00 PM

Expert Brief

The alarming statistics reveal a remarkable 30% rise in incidence over the past decade, warranting immediate attention. The speakers in this expert brief shed light on the significance of shared decision-making in screening, specifically emphasizing the target age group of 55 and above, who should undergo annual PSA blood tests.

This program series is accredited for 4 CME hours.

This program is supported by Novartis.

Author Agreement

In submitting your work (the ‚ÄúWork‚ÄĚ) for potential posting on the MDBriefCase¬†Healthcare Leadership Lab website (the ‚ÄúWebsite‚ÄĚ), you (‚ÄúYou‚ÄĚ) expressly agree to the following:

Review: MDBriefCase is pleased to consider the publication of Your Work on the Website.   The suitability of the Work for posting shall be determined by MDBRiefCase at its sole discretion. Nothing herein shall obligate MDBriefcase to post or otherwise publish the Work, or the maintain its posting in future.   

Editing; Identification: MDBriefcase shall have the right to edit the Work to conform to our standards of style, technological requirements, language usage, grammar and punctuation, provided that the meaning of the Work is not materially altered.  If posted, You will be identified as the author of the Work, or co-author if applicable.  

Grant of Rights:  As a condition of publication and for no monetary compensation, You hereby grant to MDBriefCase the following rights to the Work in any and all media whether now existing or hereafter developed, including print and electronic/digital formats:  (1) the exclusive right of first publication worldwide;  (2) the perpetual non-exclusive worldwide right to publish, reproduce, distribute, sell, adapt, perform, display, sublicense, and create derivative works, alone or in conjunction with other materials; (3) the perpetual non-exclusive worldwide right to use the Work, or any part thereof, in any other publication produced by MDBriefCase and/or on MDBriefCase’s website; and (4) the perpetual non-exclusive worldwide right to use the Work to promote and publicize MDBriefCase or its publications.  The grant of rights survives termination or expiration of this Agreement.    

Warranty:  You warrant that the Work is original with You and that it is not subject to any third party copyright; that You have authority to grant the rights in this Agreement; that publication of the Work will not libel anyone or infringe on or invade the rights of others; that You have full power and authority to enter into this Agreement; that the Work has not been published elsewhere in whole or in part; and that You have obtained permission from the copyright owner consistent with this Agreement for any third party copyrighted material in the Work.  This warranty survives termination or expiration of this Agreement.

Submission Agreement

Thank you for your interest in writing an article for the MDBriefCase Healthcare Leadership Lab website.

Audience and Appropriate Topics

The  Healthcare Leadership Lab welcomes submissions on all topics relevant to leaders in healthcare. Our topics include Leading in Healthcare, Leadership Lessons from COVID-19 and others. We prioritize stories that provide leadership advice to executives and managers in healthcare companies, offer actionable strategies for executing successful projects, and provide interesting angles on current healthcare topics. Submissions must be original work of the authors and unpublished.  When submitting, authors represent that they have included no material that is in violation of the rights of any other person or entity.

Parameters

Articles must be educational and non-promotional. If they mention the author’s company or any of the company’s products or services by name within the text, such mention should be very limited and used for reference only, not for promotion. (For example, an author might cite a survey conducted by his company but not describe his company’s product as a solution to a business problem.) Articles will be edited for clarity, style and brevity. The final headline is determined by the editor.

Length of Submissions

Guest articles for the MDBriefCase Healthcare Leadership Lab may run between 500 and 1000 words. 

Review

MDBriefCase reserves the right to accept or reject any submission  and the right to condition acceptance upon revision of material to conform to its criteria.   

No Compensation

There is no payment for contributed articles. However, MDBriefCase will give the author a byline. Authors are invited to link to the article on personal  websites, corporate websites and social media platforms.

Author Agreements

Each author understands and agrees that any submission accepted for posting is provided subject to MDBriefCase’s Author Agreement.